Skip to main content

Table 2 Univariate analysis for factors associated with response rate, progression free survival and overall survival in 355 cervical cancer patients

From: Neutrophil-lymphocyte ratio as a predictor of oncologic outcomes in stage IVB, persistent, or recurrent cervical cancer patients treated by chemotherapy

Variables

Overall response rate

Progression free survival

Overall survival

n (%)

P

HR (95% CI)

P

HR (95% CI)

P

Age, years

 < 50 (n = 157)

66 (42.0)

0.113

reference

 

reference

 

 ≥ 50 (n = 198)

67 (33.8)

 

1.091 (0.875–1.362)

0.439

1.050 (0.722–1.527)

0.797

Menopausal status

 Premenopause (n = 186)

71 (38.2)

0.773

reference

 

reference

 

 Postmenopause (n = 169)

62 (36.7)

 

1.012 (0.812–1.260)

0.917

1.002 (0.691–1.452)

0.994

Body mass index, kg/m2

 < 18.5 (n = 192)

61 (31.8)

0.003a

1.659 (1.160–2.372)

0.003

1.598 (1.035–2.466)

0.034

 18.5–24.9 (n = 50)

15 (30.0)

 

1.463 (1.139–1.879)

0.003

2.571 (1.441–4.587)

0.001

 ≥ 25 (n = 113)

57 (50.4)

 

reference

 

reference

 

Patient group

 Primary (n = 63)

22 (34.9)

0.646

reference

 

reference

 

 Persistent/recurrent (n = 292)

111 (38.0)

 

0.772 (0.582–1.025)

0.073

0.707 (0.436–1.149)

0.162

Initial FIGO stages (n = 351)

 I-II (n = 164)

66 (40.2)

0.395

reference

 

reference

 

 III-IV (n = 187)

67 (35.8)

 

1.294 (1.037–1.617)

0.023

0.915 (0.629–1.329)

0.640

Histopathology

 Non-SCC (n = 146)

60 (41.1)

0.237

reference

 

reference

 

 SCC (n = 209)

73 (34.9)

 

1.281 (1.023–1.604)

0.031

1.350 (0.920–1.980)

0.125

Disease site before chemotherapy initiation

 Locoregional (n = 138)

56 (40.6)

0.334

reference

 

reference

 

 Distant metastasis (n = 217)

77 (35.5)

 

1.353 (1.076–1.702)

0.010

1.971 (1.302–2.983)

0.001

White blood cell count, /mm3

 ≤ 10,000 (n = 300)

118 (39.3)

0.089

reference

 

reference

 

 > 10,000 (n = 55)

15 (27.3)

 

1.683 (1.252–2.263)

0.001

2.339 (1.487–3.678)

< 0.001

Neutrophil count, /mm3

 ≤ 7000 (n = 288)

114 (39.6)

0.087

reference

 

reference

 

 > 7000 (n = 67)

19 (28.4)

 

1.673 (1.268–2.208)

< 0.001

2.610 (1.706–3.993)

< 0.001

Lymphocyte count, /mm3

 ≥ 2000 (n = 44)

20 (45.5)

0.242

reference

 

reference

 

 < 2000 (n = 311)

113 (36.3)

 

1.353 (0.960–1.908)

0.085

1.545 (0.880–2.713)

0.130

NLR

 < 3.6 (n = 174)

77 (44.3)

0.010b

reference

 

reference

 

 ≥ 3.6 (n = 181)

56 (30.9)

 

1.648 (1.318–2.060)

< 0.001

2.759 (1.873–4.065)

< 0.001

Monocyte count, /mm3

 ≤ 970 (n = 348)

132 (37.9)

0.263

reference

 

reference

 

 > 970 (n = 7)

1 (14.3)

 

3.038 (1.428–6.462)

0.004

3.641 (0.884–14.994)

0.074

Eosinophil count, /mm3

 ≤ 750 (n = 340)

126 (37.1)

0.452

reference

 

reference

 

 > 750 (n = 15)

7 (46.7)

 

1.207 (0.706–2.064)

0.491

0.679 (0.215–2.138)

0.508

Hemoglobin, g/dL

 ≥ 12 (n = 93)

44 (47.3)

0.022c

reference

 

reference

 

 < 12 (n = 262)

89 (34.0)

 

1.260 (0.982–1.618)

0.069

1.308 (0.853–2.007)

0.219

Platelet count, /mm3

 ≤ 400,000 (n = 246)

95 (38.6)

0.500

reference

 

reference

 

 > 400,000 (n = 109)

38 (37.5)

 

1.560 (1.232–1.975)

< 0.001

1.963 (1.327–2.903)

0.001

  1. HR hazard ratio, CI confidence interval, FIGO the International Federation of Gynecology and Obstetrics, NLR neutrophil-lymphocyte ratio, SCC squamous cell carcinoma
  2. aStatistical significance was observed between patients with BMI ≥25 kg/m2and BMI 18.5–24.9 kg/m2, and between patients with BMI ≥25 kg/m2 and BMI < 18.5 kg/m2
  3. bOdds ratio = 1.772, 95% CI: 1.147–2.736
  4. cOdds ratio = 1.745, 95% CI: 1.079–2.823